Related Experiment Video
Updated: Jul 16, 2025

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients
Published on: February 11, 2017
Elexacaftor/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific
Minsoo Kim1, Eli Fritz McDonald2, Carleen Mae P Sabusap2
1Department of Chemistry, Vanderbilt University, Nashville, Tennessee, USA; Program in Chemical and Physical Biology, Vanderbilt University, Nashville, Tennessee, USA.
Elexacaftor (VX-445) shows variant-specific effects on cystic fibrosis transmembrane conductance regulator (CFTR) protein. Targeting translation and protein folding pathways can improve VX-445 efficacy in nonresponsive CFTR variants like P67L.
Area of Science:
- Molecular Biology
- Genetics
- Pharmacology
Background:
- Cystic fibrosis (CF) is a lethal genetic disease caused by mutations in the CFTR gene.
- CFTR correctors, like elexacaftor (VX-445), stabilize and improve CFTR protein processing.
- CFTR variants exhibit differential responses to corrector therapies.
Purpose of the Study:
- To investigate the differential response of CFTR variants P67L and L206W to VX-445.
- To elucidate the cellular mechanisms underlying CFTR biogenesis and corrector efficacy.
- To identify potential targets for sensitizing nonresponsive CFTR variants to VX-445.
Main Methods:
- Affinity purification-mass spectrometry with isobaric tandem mass tags to analyze CFTR protein-protein interactions.
- siRNA knockdown of interacting proteins, including ribosomal subunit proteins.
- Partial inhibition of protein translation.
Main Results:
- VX-445 demonstrated variant-dependent interactions with proteostasis factors involved in translation, folding, and degradation.
- Knockdown of specific interacting proteins, such as ribosomal proteins, partially rescued P67L CFTR.
- These knockdowns sensitized P67L CFTR to VX-445, enhancing trafficking correction.
- Partial inhibition of protein translation also improved P67L CFTR response to VX-445.
Conclusions:
- VX-445's mechanism of action is influenced by CFTR variant-specific proteostasis networks.
- Targeting protein translation and folding pathways can enhance the efficacy of VX-445 for nonresponsive CFTR variants.
- This study identifies potential cellular targets to improve corrector therapy for CF patients with specific mutations.
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
Leaky Scanning

